Efficacy and safety of brodalumab in subpopulations of patients with difficult-to-treat moderate-to-severe plaque psoriasis - 15/02/15
Abstract |
Background |
Novel therapies are needed for difficult-to-treat populations of patients with psoriasis.
Objective |
We sought to assess the efficacy and safety of the interleukin-17 Receptor A inhibitor brodalumab in patients with psoriasis with or without a self-reported history of psoriatic arthritis (PsA) and with or without a history of biologic use.
Methods |
Subset analyses of a phase II, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis were performed. Improvement from baseline in Psoriasis Area and Severity Index score of 75%, 90%, and 100% at week 12; static Physician Global Assessment (0/1) score; Dermatology Life Quality Index response; and Psoriasis Symptom Inventory response were evaluated within subgroups.
Results |
Efficacy and quality-of-life measures were generally similar between subgroups of patients with or without a history of PsA and with or without a history of biologic use across brodalumab doses and were significantly higher among patients who received brodalumab 140 mg every 2 weeks or 210 mg every 2 weeks versus placebo.
Limitations |
Differences between subgroups were not compared statistically, PsA was self-reported, only skin involvement/symptoms were reported, and reasons for discontinuation of prior biologic were not captured.
Conclusion |
Brodalumab is efficacious in patients with psoriasis with or without a history of PsA or biologic use.
Le texte complet de cet article est disponible en PDF.Key words : biologic, brodalumab, plaque psoriasis, psoriatic arthritis, quality of life, randomized controlled trial
Abbreviations used : DLQI, IL, PASI, PsA, PSI, Q2W
Plan
| This analysis was supported by Amgen Inc. |
|
| Disclosure: Dr Papp is a consultant, investigator, and on the speakers' bureau for AbbVie, Amgen Inc, Astellas Pharma, Bayer AG, Boehringer Ingelheim, Celgene, Forward Pharma, Galderma, Janssen Biotech Inc, Eli Lilly and Company, LEO Pharma, Merck, Novartis, Pfizer, Roche, and UCB Pharma. Dr Menter is on an advisory board for AbbVie, Allergan, Amgen Inc, Boehringer Ingelheim, Genentech, Janssen Biotech Inc, LEO Pharma, and Pfizer; is a consultant for AbbVie, Allergan, Amgen Inc, Convoy Therapeutics Inc, Eli Lilly and Company, Janssen Biotech Inc, LEO Pharma, Novartis, Pfizer, Syntrix Biosystems, Wyeth, and XenoPort Inc; is an investigator for AbbVie, Allergan, Amgen Inc, ApoPharma, Boehringer Ingelheim, Celgene, Convoy Therapeutics Inc, Eli Lilly and Company, Genentech, Janssen Biotech Inc, LEO Pharma, Merck, Novartis, Pfizer, Symbio/Maruho, Syntrix Biosystems, and Wyeth; and is on the speakers' bureau for AbbVie, Amgen Inc, Janssen Biotech Inc, LEO Pharma, and Wyeth. Dr Strober is on the speakers' bureau for AbbVie (honoraria); is a consultant for AbbVie, Amgen Inc, Celgene, Dermira, Forward Pharma, Janssen Biotech Inc, LEO Pharma, Eli Lilly and Company, Maruho, Medac Pharma, Merck, Novartis, Pfizer, Stiefel/GlaxoSmithKline, and UCB Pharma; is an investigator for AbbVie, Amgen Inc, Novartis, Eli Lilly and Company, Janssen Biotech Inc, and Merck; and receives grant support to the University of Connecticut for Fellowship Program from AbbVie and Janssen Biotech Inc. Drs Kricorian, Milmont, Nirula, and Klekotka are employees and shareholders of Amgen Inc. Dr Thompson is a former employee of Amgen Inc and is a shareholder of Amgen Inc. |
Vol 72 - N° 3
P. 436 - mars 2015 Retour au numéro
Article précédent
- Reliability of store and forward teledermatology for skin neoplasms
- Erin M. Warshaw, Amy A. Gravely, David B. Nelson
- Anatomical patterns of dermatitis in adult filaggrin mutation carriers
- Nina G. Heede, Jacob P. Thyssen, Betina H. Thuesen, Allan Linneberg, Jeanne D. Johansen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?